Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Queen Mary Hospital, Hong Kong, China.

Survival: monthsCountry:China
Toxiciy Grade:3City/State/Province:Hong Kong
Treatments:Biologic therapyHospital:Queen Mary Hospital
Drugs:Journal:Link
Date:Mar 2012

Description:

Patients:
This phase II study involved 10 advanced hepatocellular carcinoma patients who had been previously treated with the biologic therapy agent sorafenib. The median patient age was 47 years and 70% were male.

Treatment:
Patients were treated with a combination of two biologic therapy agents, bevacizumab and erlotinib (a small molecular inhibitor of epidermal growth factor receptor tyrosine kinase, which is involved in cell growth and survival).

Toxicities:
The most severe treatment-related toxicities were of grade 3 and included rash, diarrhea, and vomiting.

Results:
The median overall survival was 4.37 months.

Correspondence: Dr. Thomas Yau; email: [email protected]



Back